Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification
Classification of OTC and FTC into 3 subcategories as defined by the 2022 WHO Classification substantially improves discrimination between low-, intermediate-, and high-risk patients, especially for DSS and RAI-refractory disease.
Authors
- Evert F S van Velsen (ORCID: https://orcid.org/0000-0002-6938-065X)
- Tessa M. van Ginhoven (ORCID: https://orcid.org/0000-0002-9365-4892)
- Lindsey Oudijk (ORCID: https://orcid.org/0000-0001-6168-2381)
- Merel T Stegenga (ORCID: https://orcid.org/0009-0008-1096-8564)
- Marco Medici (ORCID: https://orcid.org/0000-0002-7271-7858)
- W. Edward Visser (ORCID: https://orcid.org/0000-0002-5248-863X)
- Folkert J. van Kemenade (ORCID: https://orcid.org/0000-0002-4225-4354)
- Robin Patrick Peeters (ORCID: https://orcid.org/0000-0001-7732-9371)
- Frederik A. Verburg (ORCID: https://orcid.org/0000-0003-1401-1993)
Institutions
- Erasmus MC (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1210/clinem/dgae581
- Citations
- 11
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.93